Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcγriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Ingrid Karlsson, Susanne Gertsson, Suzanne Kilany, Marie Borggren, Pau Abrisqueta, Ana Carneiro, Raul Cordoba, Hans Hagberg, Mats Jerkeman, Santiago Mercadal, Jonathon B. Cohen, Juan-Manuel Sancho, Ingrid Teige, Linda Mårtensson, Björn Frendéus, Andres McAllister

Blood (2021) 138 (Supplement 1): 1354.

https://doi.org/10.1182/blood-2021-147452

Published: 2021

Journal Articles

Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Alexa A Jordan, BS, Joseph McIntosh, BS, Yang Liu, PhD, Angela Leeming, William Lee, Ingrid Karlsson, PhD, Linda Mårtensson, PhD, Mathilda Kovacek, Ingrid Teige, PhD, Björn Frendéus, PhD, Michael Wang, MD, Changying Changying Jiang, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-140849

Published: 2020

Journal Articles

17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Mats Jerkeman, MD PhD, Andres McAllister, MD PhD, Carl Roos, Marie Lindell Andersson, Ingrid Karlsson, PhD, Marie Borggren, PhD, Pau Abrisqueta, MD PhD, Ana Carneiro, MD PhD, Raul Cordoba, MD PhD, Hans Hagberg, MD, Santiago Mercadal, MD, Ingrid Teige, PhD, Björn Frendéus, PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140219

Published: 2020

Journal Articles

Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration

Ingrid Karlsson, PhD, Linda Mårtensson, PhD, Marie Borggren, PhD, Mathilda Kovacek, Carl Roos, Therese Blidberg, Robert Oldham, PhD, Mats Jerkeman, MD PhD, Martin J.S. Dyer, MD PhD, Andrew Davies, MD PhD, Raul Córdoba, MD PhD, Pau Abrisqueta, MD PhD, Stephen Beers, PhD, Ingrid Teige, PhD, Andres McAllister, MD PhD, Sean H Lim, MD PhD, Mark S Cragg, PhD, Björn Frendéus, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138658

Published: 2020

Journal Articles

BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma

Changying Jiang, PhD, Yang Liu, MD, Joseph Mitchell McIntosh, Angela Leeming, Rongjia Zhang, William Lee, Krystle Nomie, PhD, Ingrid Karlsson, PhD, Linda Mårtensson, PhD, Mathilda Kovacek, Ingrid Teige, PhD, Björn Frendéus, PhD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 2863.

https://doi.org/10.1182/blood-2019-126957

Published: 2019

Journal Articles

Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412

Khiyam Hussain, Chantal E. Hargreaves, Ali Roghanian, Robert J. Oldham, H. T. Claude Chan, C. Ian Mockridge, Ferdousi Chowdhury, Bjorn Frendéus, Kirsty S. Harper, Jonathan C. Strefford, Mark S. Cragg, Martin J. Glennie, Anthony P. Williams, Ruth R. French

Blood (2015) 125 (1): 102–110.

https://doi.org/10.1182/blood-2014-08-593061

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Andrew T. Vaughan, Chisako Iriyama, Stephen A. Beers, Claude H. T. Chan, Sean H. Lim, Emily L. Williams, Vallari Shah, Ali Roghanian, Bjorn Frendéus, Martin J. Glennie, Mark S. Cragg

Blood (2014) 123 (5): 669–677.

https://doi.org/10.1182/blood-2013-04-490821

Published: 2014

Includes: Supplemental data

Journal Articles

Macrophages Activation By ICAM1 Antibody Combined With Lenalidomide Has Enhanced Anti-Myeloma Activity In a Supportive Microenvironment In Vivo and In Vitro

Sathisha Upparahalli Venkateshaiah, Ph.D., Rakesh Bam, BS, Xin Li, PhD, Khan Sharmin, MS, Ling Wen, MS, Randal S. Shelton, MS, Ingrid Teige, Björn Frendéus, Bart Barlogie, MD, PhD, Shmuel Yaccoby, PhD

Blood (2013) 122 (21): 1926.

https://doi.org/10.1182/blood.V122.21.1926.1926

Published: 2013

NARROW

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcγriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab

Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration

BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma

Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Macrophages Activation By ICAM1 Antibody Combined With Lenalidomide Has Enhanced Anti-Myeloma Activity In a Supportive Microenvironment In Vivo and In Vitro

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only